Recombitek KC2

Company: Boehringer Ingelheim Animal Health

CPIV Bbronc SWD

Dogs

1 mL

Canine Parainfluenza-Bordetella Bronchiseptica Vaccine, Modified Live Virus, Avirulent Live Culture

Recombitek KC2 Indications

This product has been shown to be effective for the vaccination of healthy dogs against canine upper respiratory infection (Kennel Cough) due to canine parainfluenza (CPIV) and Bordetella bronchiseptica.This product was licensed prior to the requirement to establish a minimum age for use.The duration of immunity has not been determined. For more information regarding efficacy and safety data go to productdata.aphis.usda.gov.

Precautions

Store out of direct sunlight at 35-46°F (2-8°C). Do not freeze. For intranasal use in dogs only. This vaccine is not to be injected. Do not mix with other products, except as specified on the label. Do not vaccinate puppies under 3 weeks of age.

Description

Recombitek^® KC2 is designed to be administered intranasally for convenient, rapid vaccination against canine upper respiratory infection (Kennel Cough). Both of the organisms in this product are widespread, common etiologic agents of this syndrome, which appears as a mild, self-limiting disease involving the trachea and bronchi of dogs of any age. It spreads rapidly among dogs that are closely confined as in hospitals, kennels, and pet stores. The disease is highly contagious and is transmitted via the airborne route.

Both of the organisms in Recombitek^® KC2 are avirulent so that they can be safely administered intranasally with little or no signs of disease. By instilling these organisms into the nasal passages, it becomes possible for these agents to infect target cells of the nasopharyngeal region, mimicking the pathogenesis of natural field infection. A very small percentage of dogs may show sneezing, coughing or nasal discharge for 3 to 10 days following vaccination. While these are usually temporary signs, consultation with a veterinarian may be indicated if they persist or progressively worsen.

Directions and dosage: Rehydrate the vaccine cake to the desired dose volume with the accompanying sterile diluent.

For 0.5 mL dose, reconstitute the dry vaccine with 0.5 mL (one-half) of the diluent.

For 1 mL dose, reconstitute the dry vaccine with 1 mL of the diluent.

Shake well and use immediately.

Field safety studies support the safety of this product when administered to puppies as young as 3 weeks of age. Using aseptic technique, immediately withdraw the rehydrated vaccine into the syringe. Use enclosed applicator tip on hub of syringe in place of syringe needle to administer the entire dose intranasally. Apply a new nasal applicator tip for each dog vaccinated. Historically, annual revaccination with this product has been recommended.The need for annual booster vaccination has not been established for this product. For advice on revaccination frequency, contact your veterinarian or the manufacturer.

Precautions

In case of anaphylactoid reaction, administer epinephrine. This product has not been tested in pregnant animals. In case of human exposure, contact a physician. Inactivate unused contents before disposal.

Preservative: Neomycin.

Recombitek^® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc.

Boehringer Ingelheim Animal Health USA Inc., St. Joseph, MO 64506

Phone: 1 (888) 637-4251

VLN/PCN 124/14M1.22

CPN: 1028317.2